The relationship between HMGB1 and immune infiltration serves as a treatment target molecule in different cancer tissues: May be used therapeutic target for possible SARS-CoV-2 infection

Basit Öğe Kaydı
dc.contributor.authorSağkan, Rahşan Ilıkçı
dc.contributor.authorAkın-Balı, Dilara Fatma
dc.date.accessioned2024-11-07T10:39:53Z
dc.date.available2024-11-07T10:39:53Z
dc.date.issued2021
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractAims: To illustrate which tumor cells may express high-mobility group box 1 (HMGB1), which is also Coronavirus disease-2019 (COVID-19) target molecule as a treatment option for possible severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) infection. Methods: We investigated m-RNA expression patterns of HMGB1 in 33 different cancer tissues. HMGB1 m-RNA expression profiles were compared with the Gene Expression Profiling Interactive Analysis database. Comparisons of promoter methylation levels with the UALCAN database were also performed. Finally, the correlation between HMGB1 and immune cells was investigated by using TIMER tool. Results: High expression profile of HMGB1 was determined in 8 different cancer tissues (colon adenocarcinoma, diffuse large B-cell lymphoma, glioblastoma multiforme, brain lower grade glioma, pancreatic adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma and thymoma) when compared with the healthy tissues (p<0.05). The promoter methylation level of HGMB1 in different cancers was significantly lower. In addition, the level of expression and overall survival did not correlate in studied tumor samples. HMGB1 transcription level was associated with innate (monocyte, neutrophil) and adaptive immune cells (cytotoxic T lymphocyte and B cell) in tumor samples. Conclusions: The use of agents that inhibit HMGB1 protein may offer an effective approach, not only against the cancer cell proliferation, but also as a strategy to minimize the possible SARS-CoV-2 infection in cancer patients with high HMGB1 expression. © 2021. by the University of Health Sciences Turkey, Gülhane Faculty of Medicine / Gülhane Medical Journal published by Galenos Publishing House. All Rights Reserved.
dc.description.sponsorshipTCGA
dc.identifier.doi10.4274/GULHANE.GALENOS.2021.1629
dc.identifier.endpage253
dc.identifier.issn1302-0471
dc.identifier.issue4
dc.identifier.scopus2-s2.0-85123080325
dc.identifier.scopusqualityQ4
dc.identifier.startpage246
dc.identifier.trdizinid515515
dc.identifier.urihttps://doi.org/10.4274/GULHANE.GALENOS.2021.1629
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/515515
dc.identifier.urihttps://hdl.handle.net/11480/11263
dc.identifier.volume63
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Publishing House
dc.relation.ispartofGulhane Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectCOVID-19
dc.subjectHMGB1
dc.subjectimmune infiltration
dc.subjectSARS-CoV-2
dc.subjecttherapy
dc.titleThe relationship between HMGB1 and immune infiltration serves as a treatment target molecule in different cancer tissues: May be used therapeutic target for possible SARS-CoV-2 infection
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu